BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Danish warship sunk by famed British admiral discovered after 225 years - 2Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- 3Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- 4Trump signs a law returning whole milk to school lunches
- 54 astronauts are now on their path to the moon. Here’s what happens next
- Zelensky sees new Russian attack threat from Belarus
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Sound Maturing: Wellbeing Tips for Each Life Stage
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- 6 Nations for Setting up camp
- Nepal’s youngest premier sworn in after releasing new rap song about unity
- The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- Porsche May Kill the Electric Boxster Before It Ever Arrives
